news

  • 6 July 2021
    Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress

    Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure 2021 Online Congress as part of the Late Breaking Science Results were also selected for the congress’ Highlights session, held virtually on 1 July 2021.

    Dr. Jeffrey Testani, Associate Professor of Medicine and Director of Heart Failure Research at Yale University School of Medicine, commented: “It was an honour to present the results from the RED DESERT study at the Heart Failure 2021 Online Congress and to be included in the Highlights session. It is encouraging to see this recognition and we are thankful to the congress team. This elegant and innovative therapeutic approach of alfapump DSR therapy demonstrated a significant improvement of cardio-renal function and a dramatic and sustained improvement in diuretic response.”

    alfapump DSR is Sequana Medical’s proprietary therapy being developed for the treatment of diuretic-resistant congestion in heart failure patients. Strong results from the RED DESERT study in eight patients with diuretic-resistant heart failure were reported in May 2021, demonstrating that repeated alfapump DSR therapy could effectively replace patients’ high dose loop diuretics and restore their diuretic response and overall cardio-renal status.